## What is claimed is:

25

- 1. Stable powderous formulations comprising a fat-soluble active ingredient in a matrix of a native lupin protein composition.
- 2. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein isolate having a protein content of more than 90 wt.-%.
  - 3. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein concentrate having a protein content of about 60-90 wt.-%.
  - 4. Formulations according to claim 1, wherein the lupin protein composition is a lupin protein flour having a protein content of about 40-60 wt.-%.
- 5. Formulations according to claim 1, comprising mixtures of native lupin protein compositions as defined in claims 2-4.
  - 6. Formulations according to claim 1, wherein the fat-soluble active ingredient is vitamin A, D, E or K, or a carotenoid, or a polyunsaturated fatty acid, or esters thereof, or mixtures thereof.
- 7. Formulations according to claim 1, wherein the fat-soluble active ingredient is a plant or animal oil or fat, particularly sunflower oil, palm oil or corn oil.
  - 8. Formulations according to claim 1, comprising additionally a reducing sugar, particularly glucose, fructose, or xylose.
  - 9. Formulations according to any one of claims 1-8, wherein the protein is cross-linked.
- 10. Food, beverages, animal feeds, cosmetics or drugs comprising a formulation according to any one of claims 1-9.
  - 11. Process for the preparation of formulations according to any one of claims 1-9, which comprises preparing an aqueous emulsion of the fat-soluble active ingredient and the native lupin protein composition, if desired, adding a reducing sugar, converting the emulsion into a dry powder, and, if required, submitting the dry powder to cross-linking the protein by heat treatment or by treatment wit a cross-linking enzyme.

WO 2004/086882 PCT/EP2004/003110

- 7 -

- 12. A process according to claim 11 wherein a reducing sugar is added and the composition is submitted to crosslinking by heating.
- 13. A process according to claim 11 wherein the composition is submitted to crosslinking by treatment with a cross-linking enzyme, particularly transglutaminase.

5

7